Clinical and angiographic results with the NIR stent: First International NIR Endovascular Stent Study (FINESS-II)

Abstract

BACKGROUND: Although safety and efficacy of the NIR ™ stent have been reported, the long-term angiographic and clinical outcomes have yet to be investigated. The FINESS-II study (First International NIR Endovascular Stent Study) was designed to assess the procedural safety of single 9 and 16 mm NIR stent implantation, the six-month restenosis rate and finally the six- and 12-month clinical outcome of patients treated with this novel coronary stent. METHODS: Patients with angina and a single de novo lesion in a native coronary artery of >3 and <5 mm diameter were included in this multicentre, prospective, observational trial. Clinical follow-up was obtained at one, six and 12 months. Angiography was performed before and after the stent implantation and at six months. The primary endpoint included major adverse cardiac events (death, myocardial infarction and target lesion revascularization) within 30 days after the procedure. Major bleeding complications and subacute stent thrombosis within the first 30 days were also reported as specific enpoints. Secondary endpoints were major cardiac-event-free survival at six- and 12- month follow-up and angiographic restenosis at six months. RESULTS: A total of 156 patients (81% male, mean age 60 &#45 10 years), with stable (54%), unstable (40%) angina pectoris or silent ischemia (6%) were enrolled. The target vessel diameter was 2.94 &#45 0.54 mm. The minimal lumen diameter pre, post and at follow-up was 1.04 &#45 0.32 mm, 2.64 &#45 0.42 mm and 1.88 &#45 0.63 mm, respectively. Restenosis rate according to the >50% diameter stenosis criterion at six month follow-up was 19% (26/136). At 12 months, the event-free survival rate was 83% (two deaths, one Q-wave and three non-Q-wave myocardial infarctions, four bypass surgery and 17 target lesion revascularizations), while 87% of the patients were free of angina pectoris. CONCLUSION: the outcome of the FINESS-II trial is comparable to those observed in previous stent trials (Benestent II), indicating that the coronary NIR stent is safe and effective as a primary device for the treatment of native coronary artery endpoints. lesions in patients with (un)stable angina pectoris. (Int J Cardiovasc Intervent 2000; 3: 143–151)

• Angina Angioplasty Anticoagulation Coronary Disease Major Adverse Cardiac Events (MACE) Nir Stent Stent